, Volume 15, Issue 1, pp 15–22 | Cite as

Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?

  • Iraklis Perysinakis
  • Chrysanthi Aggeli
  • Gregory Kaltsas
  • George N. ZografosEmail author


OBJECTIVE: Complete surgical resection is the only potentially curative treatment of localized pancreatic neuroendocrine tumors. Unfortunately, a significant proportion of these patients present with unresectable locally advanced tumors or massive metastatic disease. Recently, a new therapeutic approach for this subset of patients has emerged consisting of neoadjuvant therapy followed by surgical exploration in responders. DESIGN: We searched MEDLINE for the purpose of identifying reports regarding neoadjuvant treatment modalities for advanced pancreatic neuroendocrine tumors. RESULTS: We identified 12 studies, the vast majority of which were either case reports or small case series. Treatment options included chemotherapy, radiotherapy, peptide receptor radionuclide therapy, biological agents or various combinations of them. CONCLUSIONS: Increasing evidence supports the application of neoadjuvant protocols in advanced pancreatic neuroendocrine tumors aiming at tumor downsizing, thus rendering curative resection feasible. Given that prospective and controlled randomized clinical trials from high-volume institutions are not feasible, expert panel consensus is needed to define the optimal treatment algorithm.

Key words

Locally advanced-liver metastasis Neoadjuvant therapy Pancreatic neuroendocrine tumor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bosman FT, World Health Organization, 2010 International Agency for Research on C. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer.Google Scholar
  2. 2.
    Williams ED, Siebenmann RE, Sobin LH, World Health Organization, 1980 Histological typing of endocrine tumours. Geneva: World Health Organization.Google Scholar
  3. 3.
    Rindi G, Kloppel G, Alhman H, et al, 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449: 395–401.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Edge SB, 2010 American Joint Committee on Cancer. AJCC cancer staging manual. New York: Springer.Google Scholar
  5. 5.
    Falconi M, Bartsch DK, Eriksson B, et al, 2012 EN-ETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 95: 120–134.CrossRefPubMedGoogle Scholar
  6. 6.
    Dickson PV, Behrman SW, 2013 Management of pancreatic neuroendocrine tumors. Surg Clin North Am 93: 675–691.CrossRefPubMedGoogle Scholar
  7. 7.
    Frilling A, Clift AK, 2015 Therapeutic strategies for neuroendocrine liver metastases. Cancer 121: 1172–1186.CrossRefPubMedGoogle Scholar
  8. 8.
    Kaltsas GA, Besser GM, Grossman AB, 2004 The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25: 458–511.CrossRefPubMedGoogle Scholar
  9. 9.
    Bittoni A, Santoni M, Lanese A, Pellei C, Andrikou K, Stefano C, 2014 Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Gastroenterol Res Pract 2014: 183852.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    National Comprehensive Cancer Network (NCCN) guidelines. Available at: 2015.
  11. 11.
    Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC, 2009 Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16: 1727–1733.CrossRefPubMedGoogle Scholar
  12. 12.
    Norton JA, Harris EJ, Chen Y, et al, 2011 Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg 146: 724–732.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Doi R, 2015 Determinants of surgical resection for pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci 22: 610–617.CrossRefPubMedGoogle Scholar
  14. 14.
    Andriulli A, Festa V, Botteri E, et al, 2012 Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 19: 1644–1662.CrossRefPubMedGoogle Scholar
  15. 15.
    Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J, 2010 Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7: el000267.CrossRefGoogle Scholar
  16. 16.
    Steinmuller T, Kianmanesh R, Falconi M, et al, 2008 Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87: 47–62.CrossRefPubMedGoogle Scholar
  17. 17.
    Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR, 2009 Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev doi: 10.1002/14651858.CD007060.pub2.Google Scholar
  18. 18.
    Castellano D, Grande E, Valle J, et al, 2014 Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemother Pharmacol 75: 1099–1114.CrossRefPubMedGoogle Scholar
  19. 19.
    Karakaxas D, Gazouli M, Liakakos T, et al, 2014 Pancreatic neuroendocrine tumors: current opinions on a rare, but potentially curable neoplasm. Eur J Gastroenterol Hepatol 26: 826–835.CrossRefPubMedGoogle Scholar
  20. 20.
    Boyar Cetinkaya R, Vatn M, Aabakken L, Bergestuen DS, Thiis-Evensen E, 2014 Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. Scand J Gastroenterol 49: 734–741.CrossRefPubMedGoogle Scholar
  21. 21.
    Hodul PJ, Strosberg JR, Kvols LK, 2008 Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control 15: 314–321.CrossRefPubMedGoogle Scholar
  22. 22.
    Valle JW, Eatock M, Clueit B, Gabriel Z, Ferdinand R, Mitchell S, 2014 A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. Cancer Treat Rev 40: 376–389.CrossRefPubMedGoogle Scholar
  23. 23.
    Ferrone CR, Marchegiani G, Hong TS, et al, 2015 Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261: 12–17.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kaemmerer D, Prasad V, Daffner W, et al, 2009 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 15: 5867–5870.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Sorbye H, Westre B, Horn A, 2007 Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma. Eur J Surg Oncol 33: 1209–1210.CrossRefPubMedGoogle Scholar
  26. 26.
    Lessing Y, Ben-Haim M, Lahat G, et al, 2011 Surgery after neoadjuvant chemotherapy for locally advanced extrapulmonary poorly differentiated neuroendocrine cancer. Am Surg 77: 1102–1104.PubMedGoogle Scholar
  27. 27.
    Sato I, Ueda N, Kinoshita E, et al, 2010 Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy. Gan To Kagaku Ryoho 37: 1341–1344.PubMedGoogle Scholar
  28. 28.
    Dumont F, Goudard Y, Caramella C, Goere D, Baudin E, Elias D, 2015 Therapeutic strategies for advanced pancreatic neuroendocrine tumors with segmental portal hypertension. World J Surg 39: 1974–1980.CrossRefPubMedGoogle Scholar
  29. 29.
    Devata S, Kim EJ, 2012 Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. Case Rep Oncol 5: 622–626.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kwekkeboom DJ, de Herder WW, Kam BL, et al, 2008 Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 26: 2124–2130.CrossRefPubMedGoogle Scholar
  31. 31.
    Stoeltzing O, Loss M, Huber E, et al, 2010 Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 395: 185–192.CrossRefPubMedGoogle Scholar
  32. 32.
    Ezziddin S, Lauschke H, Schaefers M, et al, 2012 Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. Clin Nucl Med 37: 102–104.CrossRefPubMedGoogle Scholar
  33. 33.
    Sowa-Staszczak A, Pach D, Chrzan R, et al, 2011 Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging 38: 1669–1674.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Barber TW, Hofman MS, Thomson BN, Hicks RJ, 2012 The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol 38: 64–71.CrossRefPubMedGoogle Scholar
  35. 35.
    Lee J, Choi J, Choi C, Seong J, 2013 Role of radiotherapy for pancreatobiliary neuroendocrine tumors. Radiat Oncol J 31: 125–130.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2016

Authors and Affiliations

  • Iraklis Perysinakis
    • 1
  • Chrysanthi Aggeli
    • 1
  • Gregory Kaltsas
    • 2
  • George N. Zografos
    • 1
    Email author
  1. 1.Third Department of SurgeryGeneral Hospital “G. Gennimatas”AthensGreece
  2. 2.Department of PathophysiologyNational University of AthensAthensGreece

Personalised recommendations